These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 16902987

  • 1. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.
    Cancer; 2006 Sep 15; 107(6):1383-90. PubMed ID: 16902987
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
    Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL.
    Cancer Invest; 2008 Oct 15; 26(8):794-9. PubMed ID: 18798063
    [Abstract] [Full Text] [Related]

  • 4. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 15; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 5. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6512-21. PubMed ID: 15475438
    [Abstract] [Full Text] [Related]

  • 6. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):703-10. PubMed ID: 16528532
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM, Wu X, Spicer D, Groshen S, Jeffers S, Leichman CG, Leichman L, Chan KK.
    Clin Cancer Res; 1996 Sep 01; 2(9):1461-7. PubMed ID: 9816321
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.
    Cancer Chemother Pharmacol; 2007 Jul 01; 60(2):285-93. PubMed ID: 17136542
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
    Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R.
    Clin Cancer Res; 2003 Jan 01; 9(1):134-42. PubMed ID: 12538461
    [Abstract] [Full Text] [Related]

  • 13. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K.
    Oncol Rep; 2004 Feb 01; 11(2):381-7. PubMed ID: 14719072
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):173-82. PubMed ID: 16308697
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [Abstract] [Full Text] [Related]

  • 18. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
    Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL.
    Invest New Drugs; 2008 Oct 01; 26(5):445-54. PubMed ID: 18528634
    [Abstract] [Full Text] [Related]

  • 19. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C.
    Clin Cancer Res; 2003 Sep 15; 9(11):4101-7. PubMed ID: 14519632
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
    Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA.
    J Clin Oncol; 2005 Jun 10; 23(17):3912-22. PubMed ID: 15851766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.